{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-26-000004","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.254322+00:00","generated_at":"2026-05-15T23:44:49.608362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nautilus Biotechnology FY2025 net loss narrows to $59M; cash $156M; guidance for higher 2026 spend","bullets":["Q4 net loss of $13.8M vs $17.6M YoY; operating expenses down 23% to $15.4M.","FY2025 net loss of $59.0M vs $70.8M in FY2024; operating expenses fell 18% to $66.8M.","Cash and investments $156.1M as of Dec 31, 2025; management sees sufficient runway through 2027.","Early Access Program launched Jan 2026 for Tau proteoforms; no material revenue expected in FY2026.","FY2026 operating expenses expected to increase 15-20% YoY; full commercial launch targeted late 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-26-000004","json":"https://secwatch.observer/filing/0001808805-26-000004.json","markdown":"https://secwatch.observer/filing/0001808805-26-000004.md","text":"https://secwatch.observer/filing/0001808805-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000004/0001808805-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000004/naut-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:44:49.608362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}